Izotropic Appoints Breast CT Expert as Head of Imaging Technology

Vancouver, British Columbia–(Newsfile Corp. – November 5, 2021) – Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) (“Izotropic” or the “Company“), a Company commercializing a dedicated breast CT (computed tomography) imaging platform, IzoView, for the more accurate detection and diagnosis of breast cancers is pleased to announce the appointment of Dr. Andrew M. Hernandez as Head of Imaging Technology.

Dr. Hernandez has spent the last 8 years working on the design, development, and optimization of breast CT at the University of California, Davis, where he has worked under the mentorship of Dr. John M. Boone, Principal breast CT Founder and Company Director.

“Dr. Hernandez is an energetic medical physicist who has nearly a decade of experience with breast CT while working in my laboratory at UC Davis in various capacities” stated Dr. Boone. “He has measured image quality using rigorous state-of-the art metrics, developed both mathematical and physical anthropomorphic breast models based upon hundreds of breast CT images, and his comprehensive research on breast dose has established him as a world authority on radiation dosimetry for breast CT. His research has also helped shed light on the limitations of previous models for breast dosimetry in mammography, tomosynthesis, and breast CT. We are all hugely excited that he will bring his broad expertise to the design and optimization of the imaging chain for the IzoView breast CT scanner.”

As Head of Imaging Technology, Dr. Hernandez will work closely with Dr. Younes Achkire, Executive Vice President Of Product Engineering, to deliver IzoView to the market.

“The IzoView breast CT system will fully harness the capabilities of advanced x-ray imaging hardware and is designed to provide exceptional image quality for the detection and diagnosis of breast cancer while minimizing imaging time, pain and discomfort for the patient. IzoView is the culmination of decades of experience in breast CT, and I am confident that it will be a crucial modality for breast cancer diagnosis for years to come,” said Dr. Hernandez.

About Dr. Andrew Hernandez
Dr. Hernandez has a Ph.D. in Biomedical Engineering and currently holds an Assistant Professor position at the University of California, Davis, where his focus includes computer simulations and design of novel imaging modalities, assessment of model observer performance for clinically relevant tasks, and assessment of the diagnostic performance of x-ray imaging devices.

ON BEHALF OF THE BOARD
Dr. John McGraw, CEO

For investor relations inquiries, contact:

James Berard
Email: jberard@izocorp.com
Cell: 778-228-2314
Toll Free: 1-833-IZOCORP ext.1

About Izotropic Corporation

Izotropic Corporation is the only publicly traded company commercializing a dedicated breast CT imaging platform, IzoView, for the more accurate detection and diagnosis of breast cancers. To expedite patient and provider access to IzoView, Izotropic’s initial clinical study intends to demonstrate superior performance of diagnostic breast CT imaging over diagnostic mammography procedures and will initiate in Q2 2022. In follow-on clinical studies, Izotropic intends to validate platform applications including breast screening in radiology, treatment planning and monitoring in surgical oncology, and breast reconstruction and implant monitoring in plastic and reconstructive surgery.

More information about Izotropic Corporation can be found on its website at izocorp.com and by reviewing its profile on SEDAR at sedar.com.

Forward-Looking Statements

This document may contain statements that are “Forward-Looking Statements,” which are based upon the current estimates, assumptions, projections and expectations of the Company’s management, business, and its knowledge of the relevant market and economic environment in which it operates. The Company has tried, where possible, to identify such information and statements by using words such as “anticipate,” “believe,” “envision,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” “contemplate” and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words. These statements are not guarantees of performance and involve risks and uncertainties that are difficult to control or predict, and as such, they may cause future results of the Company’s activity to differ significantly from the content and implications of such statements. Forward-Looking Statements are pertinent only as of the date on which they are made, and the Company undertakes no obligation to update or revise any Forward-Looking Statements to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. Neither the Company nor its shareholders, officers, and consultants, shall be liable for any action and the results of any action taken by any person based on the information contained herein, including without limitation the purchase or sale of Company securities. Nothing in this document should be deemed to be medical or other advice of any kind.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/102084